Press Release
March 15, 2026
AIA Welcomes FDA Guidance on Accelerated mAb Approval Pathways
New framework will reduce development timelines while maintaining rigorous safety standards for variant-adapted therapies.
Research
March 8, 2026
Breakthrough Study Shows mAbs Effective Against Multiple COVID Variants
Phase 3 trials demonstrate sustained protection across emerging strains with single-dose administration.
Press Release
February 28, 2026
Coalition Calls for Expanded Access to RSV Prevention for All Infants
AIA urges policymakers to eliminate coverage barriers that prevent universal infant protection against RSV.
Opinion
February 20, 2026
Why Monoclonal Antibodies Are Essential for Pandemic Preparedness
Expert commentary on the strategic importance of mAb platforms in responding to emerging infectious threats.
Global Health
February 12, 2026
WHO Endorses mAb Strategy for Global Infectious Disease Response
World Health Organization releases new guidelines supporting monoclonal antibody deployment in low-resource settings.
Press Release
January 25, 2026
AIA Launches Healthcare Provider Education Initiative
Comprehensive training program aims to increase provider confidence in mAb therapy selection and administration.